Palbociclib is a prescription anticancer medicine classified as a CDK4/6 inhibitor. It is used in specific treatment settings for certain hormone receptor-positive, HER2-negative advanced or metastatic breast cancers according to applicable regulatory approvals.
Palbociclib 125 mg refers to one established strength of the medicine. The appropriate strength for a patient must be determined by the treating healthcare professional.
Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor, commonly called a CDK4/6 inhibitor.
Palbociclib inhibits CDK4 and CDK6, proteins involved in regulating progression through the cell cycle. In susceptible cancer cells, this can reduce progression toward cell division.
Palbociclib is used as part of treatment for certain HR-positive, HER2-negative advanced or metastatic breast cancers according to official regulatory labeling.
Palbociclib is generally classified as a targeted anticancer therapy rather than traditional cytotoxic chemotherapy.
However, it can still cause serious side effects and requires careful medical monitoring.
For approved treatment settings, Palbociclib is generally used in combination with endocrine therapy.
The exact combination depends on the patient's clinical situation and applicable prescribing information.
Commonly referenced strengths include:
- 75 mg
- 100 mg
- 125 mg
Availability may differ depending on the product and country.
Dose reduction may be necessary because of clinically significant adverse reactions, including certain blood-count abnormalities.
The treating healthcare professional determines whether a dose modification is appropriate.
Yes. Palbociclib can reduce blood-cell counts, including neutrophils.
Regular blood tests may be required during treatment.
Low neutrophil counts may increase concerns about infection.
Patients should promptly report fever or other signs of infection according to the instructions provided by their healthcare team.
Possible adverse reactions can include:
- Neutropenia
- Leukopenia
- Fatigue
- Nausea
- Diarrhea
- Decreased appetite
- Hair thinning or alopecia
The exact experience differs between patients.
Serious respiratory complications, including interstitial lung disease and pneumonitis, have been reported.
New or worsening breathing problems require appropriate medical evaluation.
Yes. Certain medicines can affect Palbociclib exposure through CYP3A-related interactions.
Patients should provide their healthcare team with a complete list of all medicines and supplements.
No. Patients should never independently increase, reduce, stop or restart Palbociclib.
All treatment changes should be directed by the healthcare team.
Follow the official instructions for your specific product or contact your healthcare provider.
Do not automatically take an additional dose to compensate.
Do not automatically take an extra dose.
Follow the product instructions or contact the healthcare team.
Palbociclib may cause harm to a developing fetus.
Patients should discuss pregnancy and contraception with their healthcare professionals.
Yes. Important information to check includes the manufacturer, active ingredient, strength, batch number, expiry date and packaging integrity.
Reliable information sources include:
- Official prescribing information
- Regulatory authorities
- The treating oncology team
- Pharmacists
- Official manufacturer information
The instructions for taking Palbociclib can depend on the specific formulation and official prescribing information for the product being used. Patients should follow the instructions provided with their medicine and by their healthcare professional.
The treatment schedule depends on the specific product, prescribed dose and treatment plan. Palbociclib is commonly administered according to treatment cycles, but the exact schedule should always be followed as prescribed by the healthcare team.
Age alone does not determine whether Palbociclib is appropriate. The healthcare team considers the patient's overall health, cancer characteristics, other medical conditions and current medicines when making treatment decisions.
Yes. Fatigue is among the possible adverse reactions reported during Palbociclib treatment. Patients experiencing significant or worsening tiredness should discuss it with their healthcare team.
Yes. Nausea and diarrhea can occur during treatment with Palbociclib. Patients should inform their healthcare professionals about persistent or severe symptoms.
Regular blood tests may be required because Palbociclib can affect blood-cell counts, including neutrophils. The healthcare team will determine the appropriate monitoring schedule.
Some vitamins, herbal products and dietary supplements may affect medicines or treatment. Patients should tell their healthcare team about all supplements before starting or continuing them.
Yes. Patients should provide a complete list of prescription medicines, over-the-counter medicines, vitamins, herbal products and supplements because some substances may interact with Palbociclib.
In some situations, a healthcare professional may temporarily interrupt treatment because of side effects, blood-test abnormalities or other clinical considerations. Patients should never interrupt treatment on their own unless instructed by their healthcare team.
Palbociclib should be stored according to the instructions provided with the specific product. Storage requirements can vary by formulation and manufacturer. Keep prescription medicines in their original packaging and away from children unless otherwise instructed by a healthcare professional.